Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6ZW61
UPID:
BBS12_HUMAN
Alternative names:
-
Alternative UPACC:
Q6ZW61; D3DNX5; Q7Z342; Q7Z482; Q8NAB8
Background:
The Bardet-Biedl syndrome 12 protein plays a crucial role in cellular processes, acting as a component of the chaperonin-containing T-complex (TRiC). This complex is pivotal in protein folding through ATP hydrolysis and is involved in the assembly of BBSome, essential for ciliogenesis and vesicle transport to cilia. Additionally, it has a significant role in adipogenic differentiation.
Therapeutic significance:
Given its involvement in Bardet-Biedl syndrome 12, characterized by severe pigmentary retinopathy, obesity, and other systemic manifestations, understanding the Bardet-Biedl syndrome 12 protein could unveil novel therapeutic strategies. Targeting its pathway may offer insights into treating or managing the syndrome's multifaceted symptoms.